[HTML][HTML] Ocular drug delivery: advancements and innovations
Ocular drug delivery has been significantly advanced for not only pharmaceutical
compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators …
compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators …
Balancing gene transfection and cytotoxicity of nucleic acid carriers with focus on ocular and hepatic disorders: evaluation of hydrophobic and hydrophilic …
FA de Oliveira, LJC Albuquerque… - Journal of Materials …, 2023 - pubs.rsc.org
Polyethyleneimine (PEI) derivatives substituted by lactose, succinic acid or alkyl domains
were evaluated as nonviral gene delivery vectors towards balancing gene transfection and …
were evaluated as nonviral gene delivery vectors towards balancing gene transfection and …
Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy
L Wang-Bishop, M Wehbe, LE Pastora, J Yang… - ACS …, 2024 - ACS Publications
Pharmacological activation of the retinoic acid-inducible gene I (RIG-I) pathway holds
promise for increasing tumor immunogenicity and improving the response to immune …
promise for increasing tumor immunogenicity and improving the response to immune …
Nucleic acid delivery to retinal cells using lipopeptides as a potential tool towards ocular gene therapies
LJC Albuquerque, FA de Oliveira… - Journal of Colloid and …, 2024 - Elsevier
We evaluated the use of lipopeptides capable to bind to nucleic acids towards plasmid DNA
(pDNA) delivery. The investigations were particularly focused on arising retinal pigment …
(pDNA) delivery. The investigations were particularly focused on arising retinal pigment …
Degradable Cationic Polycarbamates Designed for Robust IL-12 Gene Therapy against Metastatic Lung Cancer
K An, N Li, X Xu, Y Feng, P Zhao… - ACS Applied Polymer …, 2024 - ACS Publications
Polyethylenimine (PEI)-based gene carriers hold a massive promise for nonviral gene
delivery against cancers. However, their poor degradability regularly results in rather high …
delivery against cancers. However, their poor degradability regularly results in rather high …
Synthesis of Double Hydrophilic Block Copolymers Poly(2‐isopropyl‐2‐oxazoline‐b‐ethylenimine) and their DNA Transfection Efficiency
G Delecourt, L Plet, YL Guen, O Tezgel… - Macromolecular …, 2023 - Wiley Online Library
Gene delivery is now a part of the therapeutic arsenal for vaccination and treatments of
inherited or acquired diseases. Polymers represent an opportunity to develop new synthetic …
inherited or acquired diseases. Polymers represent an opportunity to develop new synthetic …
A Nanoparticle RIG-I Agonist for Cancer Immunotherapy
L Wang-Bishop, M Wehbe, LE Pastora, J Yang… - bioRxiv, 2023 - biorxiv.org
Pharmacological activation of the retinoic acid-inducible gene I (RIG-I) pathway holds
promise for increasing tumor immunogenicity and improving response to immune …
promise for increasing tumor immunogenicity and improving response to immune …
[PDF][PDF] Ocular Drug Delivery: Advancements and Innovations. Pharmaceutics 2022, 14, 1931
Ocular drug delivery has been significantly advanced for not only pharmaceutical
compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators …
compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators …
[PDF][PDF] An Introductory Review on Nanoparticles Based Treatment of Cancer
N Hanif, M Hussain, MA Raheem, T Kamran, A Malik… - 2024 - mejast.com
Cancer is a malignant disease that is the leading cause of death globally. Different
prevention and treatment techniques are used to combat such a disease with one of the …
prevention and treatment techniques are used to combat such a disease with one of the …
[引用][C] Gene Therapy & Cell Therapy
MB de Jesus - Current Gene Therapy, 2021 - ingentaconnect.com
[3] Santos HS, Rodrigues L, Vera LNP, et al. In situ gene therapy. Curr Gene Ther 2021; 21
(5): 406-30.[4] Oliveira FA, Albuquerque LJC, Delecourt G, Bennevault V, Guégan P …
(5): 406-30.[4] Oliveira FA, Albuquerque LJC, Delecourt G, Bennevault V, Guégan P …